BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 12801046)

  • 1. A phase I/II study of CHARTWEL with concurrent chemotherapy in locally advanced, inoperable carcinoma of the oesophagus.
    Harney J; Goodchild K; Phillips H; Glynne-Jones R; Hoskin PJ; Saunders MI
    Clin Oncol (R Coll Radiol); 2003 May; 15(3):109-14. PubMed ID: 12801046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-escalation with CHARTWEL (continuous hyperfractionated accelerated radiotherapy week-end less) combined with neo-adjuvant chemotherapy in the treatment of locally advanced non-small cell lung cancer.
    Saunders MI; Rojas A; Lyn BE; Wilson E; Phillips H
    Clin Oncol (R Coll Radiol); 2002 Oct; 14(5):352-60. PubMed ID: 12555873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia.
    Ikeda E; Kojima T; Kaneko K; Minashi K; Onozawa M; Nihei K; Fuse N; Yano T; Yoshino T; Tahara M; Doi T; Ohtsu A
    Jpn J Clin Oncol; 2011 Aug; 41(8):964-72. PubMed ID: 21742654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experience with dose escalation using CHARTWEL (continuous hyperfractionated accelerated radiotherapy weekend less) in non-small-cell lung cancer.
    Saunders MI; Rojas A; Lyn BE; Pigott K; Powell M; Goodchild K; Hoskin PJ; Phillips H; Verma N
    Br J Cancer; 1998 Nov; 78(10):1323-8. PubMed ID: 9823973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial.
    Budach V; Stuschke M; Budach W; Baumann M; Geismar D; Grabenbauer G; Lammert I; Jahnke K; Stueben G; Herrmann T; Bamberg M; Wust P; Hinkelbein W; Wernecke KD
    J Clin Oncol; 2005 Feb; 23(6):1125-35. PubMed ID: 15718308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High pathological response rate in locally advanced esophageal cancer after neoadjuvant combined modality therapy: dose finding of a weekly chemotherapy schedule with protracted venous infusion of 5-fluorouracil and dose escalation of cisplatin, docetaxel and concurrent radiotherapy.
    Pasini F; de Manzoni G; Pedrazzani C; Grandinetti A; Durante E; Gabbani M; Tomezzoli A; Griso C; Guglielmi A; Pelosi G; Maluta S; Cetto GL; Cordiano C
    Ann Oncol; 2005 Jul; 16(7):1133-9. PubMed ID: 15946974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accelerated hyperfractionated radiation therapy and concurrent 5-fluorouracil/cisplatin chemotherapy for locoregional squamous cell carcinoma of the thoracic esophagus: a phase II study.
    Jeremic B; Shibamoto Y; Acimovic L; Matovic Z; Milicic B; Milisavljevic S; Nikolic N
    Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1061-6. PubMed ID: 9539560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): comparison of RTOG 83-11 and RTOG 91-06.
    Komaki R; Scott C; Lee JS; Urtasun RC; Byhardt RW; Emami B; Andras EJ; Asbell SO; Rotman M; Cox JD
    Am J Clin Oncol; 1997 Oct; 20(5):435-40. PubMed ID: 9345325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction chemotherapy followed by concurrent chemotherapy and high-dose radiotherapy for locally advanced squamous cell carcinoma of the upper-thoracic and midthoracic esophagus.
    Stuschke M; Stahl M; Wilke H; Walz M; Oldenburg A; Stüben G; Seeber S; Sack H
    Am J Clin Oncol; 2000 Jun; 23(3):233-8. PubMed ID: 10857883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative chemotherapy and radiation for advanced esophageal carcinoma: comparison between once a day radiation and hyperfractionation, a single-institution experience.
    Nguyen NP; Leonardo JM; Karlsson U; Salehpour M; Vos P; Robiou C; Moran JF; Thomas P; Bullock L; Ludin A; Jendrasiak G; Sallah S
    Am J Clin Oncol; 2002 Aug; 25(4):358-64. PubMed ID: 12151965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicity and outcome of a phase II trial of taxane-based neoadjuvant chemotherapy and 3-dimensional, conformal, accelerated radiotherapy in locally advanced nonsmall cell lung cancer.
    Rojas AM; Lyn BE; Wilson EM; Williams FJ; Shah N; Dickson J; Saunders MI
    Cancer; 2006 Sep; 107(6):1321-30. PubMed ID: 16902985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hyperfractionated radiotherapy with concurrent chemotherapy for advanced esophageal cancer].
    Asakura H; Takashima H; Yokoe K; Togami T; Mitani M; Kiuchi T; Hosokawa N; Seo H; Ohkawa M
    Gan To Kagaku Ryoho; 2005 Sep; 32(9):1279-82. PubMed ID: 16184924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapidly alternating chemotherapy and hyperfractionated radiotherapy in the management of locally advanced head and neck carcinoma: four-year results of a phase I/II study.
    Leyvraz S; Pasche P; Bauer J; Bernasconi S; Monnier P
    J Clin Oncol; 1994 Sep; 12(9):1876-85. PubMed ID: 8083711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of concurrent chemotherapy, accelerated fractionation radiation, and surgery for patients with esophageal carcinoma.
    Adelstein DJ; Rice TW; Becker M; Larto MA; Kirby TJ; Koka A; Tefft M; Zuccaro G
    Cancer; 1997 Sep; 80(6):1011-20. PubMed ID: 9305700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiotherapy with high dose rate brachytherapy boost and concomitant chemotherapy for Stages IIB and III esophageal carcinoma: results of a pilot study.
    Calais G; Dorval E; Louisot P; Bourlier P; Klein V; Chapet S; Reynaud-Bougnoux A; Huten N; De Calan L; Aget H; Le Floch O
    Int J Radiat Oncol Biol Phys; 1997 Jul; 38(4):769-75. PubMed ID: 9240645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Concurrent chemoradiation with paclitaxel and platinum for locally advanced esophageal cancer].
    Zhang P; Xie CY; Wu SX
    Zhonghua Zhong Liu Za Zhi; 2007 Oct; 29(10):773-7. PubMed ID: 18396692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Phase II clinical trial of concurrent chemoradiotherapy (cisplatin plus 5-fluorouracil) for esophageal cancer].
    Lin Q; Gao XS; Qiao XY; Chen K; Wang YD; Zhou ZG
    Ai Zheng; 2008 Oct; 27(10):1077-81. PubMed ID: 18851788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose versus standard-dose radiotherapy with concurrent chemotherapy in stages II-III esophageal cancer.
    Suh YG; Lee IJ; Koom WS; Cha J; Lee JY; Kim SK; Lee CG
    Jpn J Clin Oncol; 2014 Jun; 44(6):534-40. PubMed ID: 24771865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
    Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
    J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.